Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,436,923 papers from all fields of science
Search
Sign In
Create Free Account
Tumor Escape
Known as:
Immune Evasions, Tumor
, Evasions, Tumor Immune
, Immune Evasion, Tumor
Expand
The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Antigenic Modulation
Immune Tolerance
Immunity
aspects of radiation effects
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Epigenetic inactivation of follistatin-like 1 mediates tumor immune evasion in nasopharyngeal carcinoma
Xiaoying Zhou
,
Xue Xiao
,
+10 authors
Zhe Zhang
OncoTarget
2016
Corpus ID: 2225236
Follistatin like-1 (FSTL1) is a secreted glycoprotein involved in a series of physiological and pathological processes. However…
Expand
Review
2013
Review
2013
Cancer immunotherapy: current status and future directions.
Fumito Ito
,
A. Chang
Surgical Oncology Clinics of North America
2013
Corpus ID: 5129148
2012
2012
SA-4-1BBL Costimulation Inhibits Conversion of Conventional CD4+ T Cells into CD4+FoxP3+ T Regulatory Cells by Production of IFN-γ
Shravan Madireddi
,
Rich-Henry Schabowsky
,
A. Srivastava
,
R. Sharma
,
E. Yolcu
,
H. Shirwan
PLoS ONE
2012
Corpus ID: 1401152
Tumors convert conventional CD4+ T cells into induced CD4+CD25+FoxP3+ T regulatory (iTreg) cells that serve as an effective means…
Expand
Review
2012
Review
2012
Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
S. Sapoznik
,
O. Hammer
,
+4 authors
G. Markel
Clinical and Developmental Immunology
2012
Corpus ID: 18425824
The immune system fights cancer and sometimes temporarily eliminates it or reaches an equilibrium stage of tumor growth. However…
Expand
Highly Cited
2008
Highly Cited
2008
Severe preeclampsia is characterized by increased placental expression of galectin-1
N. Than
,
O. Erez
,
+10 authors
R. Romero
Journal of Maternal-Fetal & Neonatal Medicine
2008
Corpus ID: 13769881
Objective. Galectin-1 is a major anti-inflammatory protein expressed by the placenta and immune cells that can bias the character…
Expand
Review
2007
Review
2007
Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance
P. Roda-Navarro
,
H. Reyburn
The FASEB Journal
2007
Corpus ID: 43105808
Immune synapses (IS) are supramolecu‐lar clusters providing intercellular communication among cells of the immune system. While…
Expand
2007
2007
The role of TGF-beta-1 protein and TGF-beta-R-1 receptor in immune escape mechanism in bladder cancer.
A. Helmy
,
O. Hammam
,
Tarek Ramzy El Lithy
,
Mohamed Mohi El Deen Wishahi
MedGenMed : Medscape general medicine
2007
Corpus ID: 24798923
Highly Cited
2003
Highly Cited
2003
Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells
V. Makarenkova
,
G. Shurin
,
+6 authors
M. Shurin
Journal of Neuroimmunology
2003
Corpus ID: 31066255
Review
1999
Review
1999
Autoaggression and tumor rejection: it takes more than self‐specific T‐cell activation
R. Ganss
,
A. Limmer
,
T. Sacher
,
B. Arnold
,
G. Hämmerling
Immunological Reviews
1999
Corpus ID: 11875679
Summary: Establishment of self‐tolerance prevents autoaggression against organ‐specific self‐antigens. This beneficial effect…
Expand
Highly Cited
1998
Highly Cited
1998
Expression of Fas(APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma.
G. Cardi
,
J. Heaney
,
A. Schned
,
M. Ernstoff
Cancer Research
1998
Corpus ID: 38408211
The functional expression of Fas-ligand on tumor cells reported in a variety of neoplasms has been proposed by several groups as…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE